Foundation for Neglected Disease Research (FNDR) is a not-for-profit biotech R&D organiza-tion focusing on discovery and development of drugs, diagnostics and solutions for infectious diseases which have a high socio-economic impact, such as tuberculosis, malaria, dengue, rabies, leishmania, and more recently COVID-19.
Since its inception in 2014, FNDR has won numerous Indian and international awards and grants in areas of tuberculosis, bacterial biomarkers, malaria, including multiple grants from Government of India. FNDR also holds patents on various drug candidates, one of which is in Phase 2 clinical trial for tuberculosis, in collaboration with Bill and Melinda Gates Medical Research Institute and Global TB Alliance (https://clinicaltrials.gov/ct2/show/NCT04176250).
FNDR has a team of 16 scientists, consisting of medicinal chemists, microbiologists, immunologists, molecular biologists, biochemists, pharmacologists, veterinarians, and peo-ple with drug development and techno-commercial expertise ranging from 2-25 years, and have collectively delivered over 20 clinical candidates for various indications.
FNDR is housed in a 10,000 sq. ft. R&D Centre in north Bangalore, India. It has state-of-the-art BSL-2 and BSL-3 facilities with both in-vitro and in-vivo capabilities, including ani-mal biocontainment units with individually ventilated cages (IVC’s). The facility also has a complete set-up with DMPK, Bioanalytical and Chemistry and virology labs for drug discov-ery. The In-vitro and in-vivo BSL-3 biosafety containment laboratories are registered with the Department of Biotechnology (DBT), Institutional Biosafety Committee (IBSC), and CPCSEA-Institutional animal ethics committee (IAEC).
H3D pioneers world-class drug discovery in Africa and is known for its breakthrough research on malaria. The Centre focuses on discovering novel medicines for infectious diseases that predominantly affect African populations, with malaria, tuberculosis, AMR and COVID-19 in its current portfolio. Towards addressing health inequalities, H3D is also developing technology platforms that will allow for the customization of medicines to African patients’ needs. At H3D, African scientists can utilize their scientific skills and education to improve the health of African patients and to educate the next generation of African scientists. Innovation and skills development are at the core of H3D’s work. The Centre supports partnerships that will enable Africa to become more self-reliant and a global player in innovative pharmaceutical research and development. As the first and only centre of its kind on the African continent with world-class infrastructure, H3D undertakes drug discovery underpinned by the integration of chemistry, biology, and pharmacology, including drug metabolism and pharmacokinetics. Biotechnology.
Founded in 1906, Leitat is one of the reference entities at state and European level in technology management. It has a team of more than 400 professionals, experts in applied research, technical services and management of technological and innovation initiatives. Leitat provides social, industrial, economic and sustainable value, offering comprehensive solutions in multiple sectors and areas: development of new materials, eco-sustainable production, occupational health prevention systems, revaluation of waste and use of natural resources, interconnectivity and digitization of industry, green energy and maximization of energy efficiency. Leitat is recognized by the Ministry of Economy, Industry and Competitiveness and is one of the main entities participating in the Horizon2020 program of the European Union.